title: Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy.
abstract: Paclitaxel is a widely used chemotherapy agent that has rarely been associated with ophthalmic toxicities. Cystoid macular edema is one such rare side effect of paclitaxel therapy. Its pathophysiology remains poorly understood. Here, we report on a 69-year-old woman who developed cystoid macular edema associated with the albumin-bound formulation of paclitaxel after several months of therapy for breast cancer. After 2 months of drug withdrawal, her vision improved and there was a significant improvement in the macular edema by imaging with spectral-domain optical coherence tomography. Oncologists using taxane agents should be aware of this rare adverse outcome for timely patient referral to an ophthalmologist and appropriate treatment to preserve a patient's visual acuity.
authors.affiliation: aDepartment of Internal Medicine, New York University School of Medicine bDepartment of Ophthalmology, Mount Sinai School of Medicine, New York, New York, USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Park
authors.forename: Naomi R
authors.initials: NR
authors.lastname: Goldberg
authors.forename: Sylvia
authors.initials: S
authors.lastname: Adams
mesh_terms: D000368:Aged; D000418:Albumins / Q000009:adverse effects* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008269:Macular Edema / Q000139:chemically induced*; D009901:Optic Nerve Diseases / Q000150:complications; D017239:Paclitaxel / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel